PMLiVE7d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE7d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE8d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...
PMLiVE9d
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...
PMLiVE10d
AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra
AstraZeneca (AZ) and Avillion have shared positive results from a phase 3b trial of their inhaled anti-inflammatory rescue medication in asthma patients aged 12 years and older. Airsupra ...
PMLiVE10d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and Astellas’ Xtandi (enzalutamide) in patients with metastatic castration-sensitive ...
PMLiVE10d
Navigating US payer evidence needs to optimise market access
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be ...
PMLiVE10d
AbbVie shares promising late-stage results for Parkinson’s disease candidate tavapadon
AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...
PMLiVE11d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...
PMLiVE11d
ABPI highlights importance of NHS-industry partnerships in improving patient outcomes
Hospitals engaging in industry partnerships were found to be up to 2.5 times more likely to follow NICE guidelines Research commissioned by the Association of the British Pharmaceutical Industry (ABPI ...
PMLiVE11d
Medscape Education Breathes Life Into Pulmonology: Showcasing Success at CHEST 2024
Medscape Education showcases its strong track record in providing high-quality education in the field of pulmonology at the annual conference of the American College of Chest Physicians in Boston, ...